EndoRotor® Ablation of Barrett's Esophagus: Safety and Feasibility Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-27

Study Completion Date

2019-06-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the safety and feasibility of the EndoRotor® for the ablation of Barrett's esophagus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium

NCT02249975

Barrett's Esophagus

COMPLETED NA

Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy

NCT02106910

Barrett's Esophagus

COMPLETED NA

Application of hybridAPC in the Treatment of Barrett

NCT03418584

Barrett's Esophagus

UNKNOWN NA

Ultralong-segment Barrett's Esophagus: Towards a Capsule-sponge Surveillance Strategy

NCT06720636

Barrett Esophagus

RECRUITING NA

The Efficacy and Patient Tolerance of Ultrathin Nasal Endoscopy to Detect Barrett's Oesophagus

NCT02498041

Barrett's Esophagus Dyspepsia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective pilot study, to be performed in 30 patients with Barrett's esophagus that have an indication for ablation treatment. These include patients with low grade dysplasia (LGD), high grade dysplasia (HGD) or residual Barrett's after a complete endoscopic resection of a lesion containing HGD or esophageal adenocarcinoma. Ablation treatment will be performed by the EndoRotor ablation device, followed by surveillance endoscopy at 3 months where the feasibility for ablation will be assessed. During the 3 months follow-up, all adverse events such as perforation, post-procedural bleeding, stricture, and pain will be registered.

The EndoRotor® System is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. The EndoRotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Barretts Esophagus With Dysplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EndoRotor® ablation

Prospective pilot study, to be performed in 30 patients with Barrett's esophagus that have an indication for ablation treatment. Barrett's ablation will be performed using the EndoRotor®.

Group Type EXPERIMENTAL

The EndoRotor®

Intervention Type DEVICE

The EndoRotor® is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. The EndoRotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The EndoRotor®

The EndoRotor® is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. The EndoRotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent.
* Age equal to or above 18 years (adult).
* Minimum (residual) Barrett's length of 2 cm and a maximum length of 5 cm (C0-5M2-5 according to the Prague classification)
* Scheduled Barrett's ablation for:

* Histologically proven intestinal metaplasia with either high- or low-grade dysplasia in the absence of any visible lesion,
* Residual Barrett's mucosa after complete endoscopic resection (for visible lesions containing HGD or EAC.) (EMR \<50% of the circumference)
* Favorable anatomy (e.g. straight esophagus, no previous anti-reflux procedure) that allows performing endoscopic treatment with the EndoRotor®.

Exclusion Criteria

* Presence of a visible lesion suspicious of early esophageal cancer or has a high chance of harboring cancer, or biopsy proven cancer.
* In case of previous EMR: EMR specimen showing deep submucosal invasion (\> 500μm), poorly to undifferentiated cancer (G3 or G4), lymphovascular invasion, or positive vertical margins.
* In case of previous EMR: \> 50% circumference.
* Any prior endoscopic ablation treatment or dilation for esophageal stenosis.
* Significant esophageal stenosis, preventing the passage of the therapeutic endoscope.
* Evidence of portal hypertension, esophageal varices, etc.
* An interval \< 6 weeks between EMR and EndoRotor treatment.
* An interval of \> 6 months after the last high resolution endoscopy with biopsies containing low or high grade dysplasia.
* Unable to undergo endoscopic procedure using sedation analgesics.
* Anti-coagulant therapy (apart from monotherapy aspirin) that cannot be discontinued prior to the procedure, OR uncorrectable hemostatic disorders.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No